Portola Pharmaceuticals, Inc.
PTLA
PTLA was delisted on the 1st of July, 2020.
181 hedge funds and large institutions have $1.37B invested in Portola Pharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 60 increasing their positions, 56 reducing their positions, and 47 closing their positions.
7% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 56
3% less call options, than puts
Call options by funds: $28.8M | Put options by funds: $29.7M
8% less funds holding
Funds holding: 197 → 181 (-16)
27% less capital invested
Capital invested by funds: $1.88B → $1.37B (-$513M)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
30% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 47
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cadian Capital Management
New York
|
+$47.5M |
| 2 |
Morgan Stanley
New York
|
+$42.1M |
| 3 |
William Blair Investment Management
Chicago,
Illinois
|
+$22.8M |
| 4 |
JSP
Jackson Square Partners
Larkspur,
California
|
+$19.1M |
| 5 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
+$11.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$123M |
| 2 |
ZCI
Zevenbergen Capital Investments
Edmonds,
Washington
|
-$30.3M |
| 3 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$20.1M |
| 4 |
ECAU
Everett Capital Advisors (UK)
London,
United Kingdom
|
-$17.6M |
| 5 |
PC
PointState Capital
New York
|
-$17.6M |
PTLA Hedge Fund Activity: Q4 2018 in Review
181 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q4 2018, worth a combined $1.37B — down 27% from $1.88B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of PTLA and 33 opened new positions — a net loss of 14 holders — while 56 trimmed existing stakes and 60 added.
The largest buyer was Cadian Capital Management, adding an estimated $47.5M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $123M sold.
- 181 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q4 2018, down from 197 in Q3 2018.
- Funds reported $1.37B of Portola Pharmaceuticals, Inc. stock for Q4 2018, down 27% quarter-over-quarter.
- 33 funds opened new Portola Pharmaceuticals, Inc. positions in Q4 2018 and 47 closed out, a net change of -14 holders.
- The largest Portola Pharmaceuticals, Inc. buyer in Q4 2018 was Cadian Capital Management, an estimated $47.5M added.
- The largest Portola Pharmaceuticals, Inc. seller in Q4 2018 was PFM Health Sciences, an estimated $123M sold.
Based on aggregated 13F filings for Q4 2018.